#AANAM – Soliris Has Long-term Relapse Prevention
Soliris (eculizumab) significantly reduced the risk of disease relapses in people with neuromyelitis optica spectrum disorder (NMOSD) over nearly three years, according to new data from the clinical trial PREVENTÂ and its extension study. Additional findings project that long-term Soliris treatment may reduce relapse risk over the course of…